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In this paper the Rotterdam Elderly Study is presented. The aim of the study is to investigate 
determinants of disease occurrence and progression i the elderly. In addition to contributing toour 
understanding of the etiology of geriatric illnesses, the study is expected to lead to specific 
recommendations for intervention. The study focusses on causally related eterminants of major 
diseases in the elderly. Fields of interest for the Rotterdam Elderly Study are conditions which 
interfere the most with the quality of life for the elderly. The aims of the Rotterdam Elderly Study 
are: 
(1) To investigate, by means of epidemiologic, clinical and basic research, the determinants of 
diseases in order to assess their etiologic significance. 
(2) To investigate potentially modifiable determinants in order to be able to develop reventive 
strategies by providing specific recommendations for intervention studies. 
The Rotterdam Elderly Study focusses on four primary areas of research: neurogeriatric 
diseases, cardiovascular diseases, locomotor diseases and ophthalmologic diseases. It is a 
prospective follow-up study, in which determinants of disease and determintants of progression of
disease will be investigated in the total population of 55 years or over of the district of Ommoord in 
Rotterdam. It is anticipated that about 10,000 people will participate in the study and they will be 
examined in the period of 1991 to 1995. 
1. GENERAL DESCRIPTION OF THE ROTTERDAM 
ELDERLY STUDY 
1.1. Int roduct ion 
Due to increased longevity in the last decades, the 
elderly form a substantial and growing part of the 
popu la t ion .  Age- re la ted  i l lnesses  w i th  chron ic  
1 Corresponding author. 
character i s t i cs ,  e.g. A l zhe imer ' s  d i sease ,  v i sua l  
impairment, cardiovascular and locomotor diseases, 
affect large numbers of people and have a dramatic 
impact on the quality of life. It is obvious that a delay 
in the onset of  chronic diseases wil l  reduce the time 
spent with some form of disabi l i ty and may l imit the 
o therwise  expected  reduct ion  in qua l i ty  of  l i fe.  
However,  before interventive action can be advocated 
with conf idence  more  must  be known about the 
etiology of geriatric diseases, especial ly with respect o 
potential ly modi f iable r isk factors. The Rotterdam 
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Elderly Study focusses on the study of etiology by 
investigating the incidence and determinants of 
occurrence of important chronic diseases. The 
investigation of potentially modifiable risk factors is 
one of the major objectives of the Rotterdam Elderly 
Study. This knowledge may lead to the testing of 
specific preventive and therapeutic measures by 
randomized controlled trials in defined high-risk 
groups. The primary target is improvement in quality of 
life by reducing morbidity in the elderly. 
1.2. The Rotterdam Elderly Study, scope of research 
80 
spectacularly, life expectancy atmiddle and old age has 
also increased somewhat (Figure 2). Assuming that the 
life span of the human species is finite and close to that 
of today, a continuation of the squaring of the survival 
70 
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The Rotterdam Elderly Study is a longitudinal 60 
population study designed to investigate determinants 
of the incidence and progression of diseases in the 
elderly. The aims of the study are two-fold: 
(1) To investigate, by means of epidemiologic, so 
clinical and basic research, determinants of chronic 19o0 
diseases in order to assess etiologic significance. 
(2) To invest igate potent ia l ly  modi f iab le  
determinants in order to be able to provide specific years 
recommendations that, once confirmed by intervention 20 
studies, may be developed into preventive strategies. 
The study focusses on four primary areas of research: 
neurogeriatric diseases, cardiovascular diseases, 18 
locomotor diseases and ophthalmologic diseases. The 
primary and secondary research questions in each of 16 
these areas are described in chapter 2. 
1.3. Rationale 
The number of elderly patients with chronic 
illnesses is rising rapidly. The mean duration of life is 
longer than ever, but the quality of life in the years of 
old age seems to be declining (96). Life expectancy at 
birth has been increasing since the beginning of this 
century, for the most part due to diminished perinatal 
and infant mortal ity (Figure 1), Although less 
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Figure 2. 
Life expectancy at birth (upper part) and at age 65 years (lower 
part) of men and women, The Netherlands. 
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Survival curves for men and women, 1900 and 1985, The 
Netherlands. 
curve with time (Figure 1) is to be expected. This 
process is described as the compression f mortality 
(28). Today, however, when there is a fair chance of 
reaching the 7th decade, it is not a further increase in 
life expectancy at that age but improvement in health 
and well-being which deserves priority. A major 
contribution to quality of life of the elderly may be 
achieved when postponement of the onset of chronic 
illnesses is realized. Therefore, there is a clear need for 
preventive measures aimed at the compression of 
morbidity in the elderly (29, 34, 61). 
Prevention, however, requires specific knowledge of 
determinants of the disease at issue. The discipline of 
epidemiology is concerned with the study of disease 
occurrence, especially the association of disease 
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occurrence or prognosis with putative determinants. 
Putative risk factors of disease or disease progression 
are best studied in collaboration with other disciplines 
of medical science to determine their clinical and 
etiologic relevance. 
The research projects of the Rotterdam Elderly 
Study focus on those age-related conditions that 
significantly contribute to chronic illness and disability 
in the aged population: dementia, cardiovascular 
diseases, osteoporosis and osteoarthritis, and visual 
impairment. Some selected ata on the frequency of 
occurrence of these diseases is shown in Figures 3, 4 
and 5. 
The investigation of potentially modifiable risk 
factors, one of the aims of this study, is motivated by 
the fact that it may be possible to develop preventive 
strategies. Prevention of illness and disability is the 
natural first step toward eliminating disease-induced 
impairment of the quality of life. There are no a priori 
grounds for assuming that preventive strategies for the 
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Figure 5. 
Average incidence rate (per 1000 personyears) of hospitalisation 
for cerebro-vascular accident in The Netherlands, 1986. 
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Figure 3. 
Average incidence rate (per 1000 personyears) of hospitalisation 
for dementia, in Rotterdam, The Netherlands, 1981 - 1985. 
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Figure 4. 
Average incidence rate (per1000 personyears) of hospitalisation 
for hip fracture in The Netherlands, 1967 - 1979. 
aged would not be worthwhile (29). The medical 
examination of healthy subjects who do not directly 
benefit from this procedure is justified by the fact that 
epidemiologic research of the past wenty years has 
contributed significantly to current knowledge of 
chronic disease tiology. 
1.4. Design of the Rotterdam Elderly Study 
1.4.1. Overview 
The Rotterdam Elderly Study is a prospective 
follow-up study. All participants are extensively 
examined at the time of enrollment. After 2.5 years 
every participant will be re-examined using identical 
procedures. Incident morbidity, changes in disease 
determinants and, eventually, cause-specific death will 
be recorded. Comparison with baseline data will 
provide estimates of incidence. Moreover, it will be 
possible to investigate the occurrence of disease with 
respect to specific determinants efficiently by the case- 
control approach within the cohort. 
1.4.2. Study cohort 
The study cohort was defined as all inhabitants 
aged 55 years and older of one district of Rotterdam 
(Ommoord), who live there at a specific point in time 
and are willing to participate in the study. Potential 
participants will be invited in random clusters. Names 
and addresses will be drawn from the municipal register 
which is reliable, complete and up to date. The number 
of eligible subjects is 11,850 (see Table 1). The 
response rate, according to the results of a pilot study, 
is expected to be over 80 per cent. 
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TABLE 1, - Demographic data for the district of 
Ommoord in Rotterdam. 
age number of men number ofwomen total 
55-59 904 1,040 1,944 
60-64 917 1,032 1,949 
65-69 841 1,090 1,931 
70-74 685 1,014 1,699 
75-79 549 964 1,513 
80-84 344 1,007 1,351 
85-89 239 762 1,001 
90+ 94 372 466 
TotN 4,573 7,281 11,854 
* Socio-economic data: social and economic status, 
housing and living conditions. 
* Geriatric status: mental status questionnaires, 
mobility. 
* Physical examination: anthropometry, 
sphygmomanometry, neurologic examination. 
* Ophthalmologic examination: visual acuity, 
tonometry, fundus photography, perimetry. 
* Additional measurements: electrocardiography, 
ultra-sonographic examinations of carotid and 
aortic vessel walls, radiography, dual X-ray 
absorptiometry. 
* Laboratory examination: samples of blood and 
urine are collected for hemostatic determinations, 
routine clinical chemistry and specific additional 
tests. 
1.4.3. Protocol 1.6. Time schedule 
To obtain baseline data an initial home visit and 
interview by a trained research assistant will be 
followed by a physical examination. Health status, 
putative risk factors, and anthropometric and clinical 
variables will be assessed in a standardized manner by 
trained paramedical assistants and physicians. The 
medical examination will be performed at the field 
center of the Rotterdam Elderly Study, located in the 
heart of the district of Ommoord. At  follow-up, about 
2.5 years after enrollment, changes in health status and 
clinical measurements will be assessed by re- 
examination atthe center. Incident cases of disease, as 
well as cause-specific deaths will be monitored uring 
the study period by observing the diagnostic procedures 
of the formal health care system. Thus, essential data on 
morbidity endpoints and vital status will be available 
for conclusions based on person-time-related 
observations. 
The Rotterdam Elderly Study entered its pilot phase 
in 1989. Full participant recruitment and complete data 
acquisition started in 1990. Follow-up examinations 
will start in January 1993. The whole study inexpected 
to run until 1995. 
2. RESEARCH PROJECTS 
The Rotterdam Elderly Study has research projects 
in four areas: neurogeriatric diseases, cardiovascular 
diseases, locomotor diseases and ophthalmologic 
diseases. The aims and design of these projects will be 
described in some detail here. 
2.1. Neurogeriatric diseases 
2.1.1. Introduction 
1.4.4. Informed consent 
The Rotterdam Elderly Study has been approved by 
the Medical Ethics Committee. Each eligible person 
will receive written and oral information about the 
goals and research methodology of the study, together 
with a description of the examinations involved. 
Respondents will be asked to sign a consent form. 
1.5. Measurements 
A short list of the baseline measurements is given 
here. For a detailed escription of the measurements the
reader is referred to the Manual of Operations of the 
Rotterdam Elderly Study, which is available upon 
request. 
* Medical data: medical history, dietary history, 
present medical complaints, pharmacotherapy, use
of medical services. 
The neurogeriatric diseases, including dementia 
and Parkinson's disease, are major public health 
problems. The frequency of dementia is, even 
according to conservative estimates, very high (37, 86). 
Recent evidence suggests that he prevalence of severe 
dementia n the Netherlands is at least 5% of those aged 
65 years or over, and 25% of those aged 85 years or 
over (43). The prevalence of both dementia nd 
Parkinson's disease rises sharply with age. The burden 
of these diseases, for patients and their families a  well 
as the community, is very high. The economic osts of 
dementia nd Parkinson's disease, in particular for 
nursing home care, are enormous and will continue to 
increase with the rising prevalence ofthe diseases. It is 
estimated that by the year 2000, psychogeriatric 
nursing home costs will grow from 33% to 42% of the 
Dutch national mental health care budget (6). These 
considerations have led to the present study of the 
incidence and risk factors of the dementing illnesses 
and the prevalence of Parkinson's disease. 
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2.1.2. Research questions 
1. What is the incidence of dementia, specifically 
Alzheimer's disease, vascular dementia, mixed 
dementia and other dementia's? 
2. What are the risk factors for the various types of 
dementia? 
3. What is the prevalence of Parkinson's disease 
among the elderly? 
2.1.3. Rationale 
Dementia is one of the most important causes of 
severe disability in the elderly. Research into the 
frequency of the dementing illnesses has been limited 
so far to studies of the prevalence and incidence of 
hospitalization for dementia (43, 86). However, a 
sizable proportion of the patients suffering from 
dementia re not admitted to hospitals or nursing 
homes. This applies in particular for dementia 
occurring at a late age, e.g. after the age of 70. The lack 
of information about he true incidence of dementia is
an important motive for the present study. From an 
etiologic viewpoint it is important o distinguish 
between the various forms of dementia that have a 
different pathophysiological b ckground (16, 35, 39, 
62, 108). For studies on the incidence of the dementing 
illnesses this implies that diagnostic facilities have to be 
available in order to be able to diagnose the subtypes of 
dementia, nd that he size of the study cohort has to be 
sufficient to obtain stable estimates of the incidence for 
each subtype. The major subtypes considered in this 
study are: Alzheimer's disease, vascular dementia, 
mixed dementia and other dementia's. 
The primary aim of this study is to identify 
preventable causes of the dementing illnesses, by 
investigating risk factors for dementia. This study will 
provide data that may lead to further intervention 
research aimed at preventing dementia. The following 
putative risk factors are considered important inview of 
the possibilities for prevention: 
(1) Vascular factors: (35, 91) vascular (multi- 
infarct) dementia s likely to be strongly associated with 
both atherosclerosis and risk factors for cardiovascular 
disease (see also chapter 2.2). Intervention i factors 
that cause atherosclerotic vascular lesions appears to be 
a likely means of reducing loss of cognitive function. 
(2) Traumatic factors: (3, 12, 41, 69, 98) head 
trauma is in principle a preventable cause of dementia. 
This is particularly the case because head trauma may 
be an important cause of dementia in terms of 
attributable risk. 
(3) Toxicologic and nutritional factors:(94) 
aluminum intake has been implicated in the etiology of 
Alzheimer's disease; other micronutrients, particularly 
selenium, have also been suggested as risk factors for 
dementia. 
It is essential to study the role of genetic factors in 
the etiology of Alzheimer's disease, because of the 
interactions between genetic factors and other risk 
factors (42). As far as prevention is concerned this 
implies that it is necessary toidentify those individuals 
who are susceptible toenvironmental risk factors. This 
underlines the importance ofin-depth studies of genetic 
factors in those known to have other putative risk 
factors for the dementing illnesses. Therefore, the need 
for joint epidemiologic, molecular biological and 
immunologic studies is emphasized (see subprojects in
2.1.5). 
2.1.4. Study design 
2.1.4.1. General design 
The study is designed as a prospective follow-up 
study. In the initial phase of the study (baseline 
examination) patients already suffering from dementia 
will be detected. In this initial phase putative risk 
factors for dementia will be measured. Subjects who are 
free of dementia t the first examination will be re- 
examined after an average of 2.5 years. This follow-up 
study will yield new cases of dementia, which will 
enable us to estimate the incidence rate of dementia and 
its subtypes. It is estimated that at least 180 new patients 
with dementia will occur in about 22,000 person-years 
(about 10,000 subjects followed for an average of 2.5 
years, after subtraction ofdeaths). This is considered to
be sufficient o obtain a stable estimate of the 
incidences of Alzheimer's diseage, vascular dementia, 
mixed dementia nd other dementia's. These 180 
incident cases will also suffice to investigate potential 
risk factors for dementia and its subtypes. 
Methodology 
The incidence study will be performed as part of an 
investigation fvariations in the incidence of dementia 
in countries of the European Community. An 
adaptation of the Geriatric Mental State (GMS) in 
combination with the Mini Mental State Examination 
(MMSE) will be used as screening instrument in the 
initial phase of the study (18, 22, 49). The GMS yields 
a preliminary diagnosis of dementia t 6 levels of 
diagnostic reliability. It is expected that approximately 
20% of the initial group will be positive according to the 
GMS. This group will undergo asecond examination to 
confirm the diagnosis of dementia. Upon confirmation 
a specific neurologic and geriatric examination will be 
conducted, including laboratory tests and Magnetic 
Resonance Imaging (MRI). 
Putative risk factors 
The aim of the study is to detect preventable causes of 
dementia. During the initial phase (baseline 
examination) a variety of possible determinants of the 
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incidence of dementia will be measured. The putative 
risk factors are separated into the following major 
categories: genetic factors, vascular factors, 
immunologic factors, virologic factors, toxicologic 
factors, nutritional factors and traumatic factors. 
* Genetic factors: family history of dementia, 
Down's syndrome, leukemia, Parkinson's disease, 
epilepsy; 
* Vascular factors: atherosclerotic vessel lesions, 
blood pressure, lipids, smoking habits; hemostatic 
variables; 
* Immunologic factors: family history of (auto) 
immune diseases; serology of bacterial infections; 
auto-immune antibodies; 
* Virologic factors: history of virus infection; titers 
of neurotropic viruses; 
* Toxicologic factors: occupational risk, medication, 
aluminum; 
* Nutritional factors: micronutrient intake; alcohol 
intake; 
* Traumatic factors: head trauma, anesthesia. 
2.1.5. Specific projects 
(1) Genetic factors: molecular linkage analysis 
In several families Alzheimer's disease segregates 
as an autosomal dominant disorder. In these families, 
molecular genetic studies have suggested linkage to 
polymorphic DNA markers on the proximal long arm of 
chromosome 21. In the Rotterdam Elderly Study, full 
pedigree information on the history of dementia in first 
degree relatives will be obtained from all subjects. 
Families with more than one dementia patient will enter 
an ongoing genetic study of familial Alzheimer's 
disease. In this study molecular linkage analysis with 
recently developed polymorphic markers, in order to 
localize the putative Alzheimer's gene on chromosome 
21, will be carried out. The presence of polymorphic 
markers on chromosome 21 will be compared between 
patients with early and late onset familial Alzheimer's 
disease. 
(2) Genetic factors: ONA repair 
Several studies have reported decreased DNA 
repair in patients with Alzheimer's disease. It has been 
hypothesized that this defect leads to an accumulation 
of lesions in the central nervous ystem and may thus 
play a role in the pathogenesis ofAlzheimer's disease. 
In this project, DNA repair in all incident Alzheimer 
patients and age- and sex-matched controls drawn 
randomly from the study population will be compared. 
There is evidence that a decrease in DNA repair is 
specific for the subpopulation of familial Alzheimer 
patients, whose disease is most likely of genetic origin. 
Therefore, comparisons will be made between familial 
patients (those with one or more relatives with 
dementia) and sporadic patients. To determine whether 
the defect in DNA repair precedes the first symptoms of 
disease, the offspring of patients from families in which 
Alzheimer's disease is apparently inherited as an 
automosal dominant disorder will also be examined. 
(3) Immunologic factors 
The aim of the immunologic project in the 
Rotterdam Elderly Study is to investigate impaired T 
cell reactivity in patients with Alzheimer's disease. For 
this purpose, responses of T cells in all incident 
Alzheimer patients and age- and sex-matched controls 
drawn randomly from the cohort will be compared. 
First, the capacity of T cells to divide, produce hormone 
or lymphokines and express receptors following 
stimulation will be studied. Secondly, the possibility of 
improving the reactivity of T cells from Alzheimer 
patients with the help of lymphokines and 
neuroendocrine hormones will be investigated. Patients 
with Alzheimer's disease will be followed to assess the 
relationship between T cell reactivity and severity of 
the disease. Moreover, familial patients (those with one 
or more relatives with dementia) and sporadic patients 
will be compared to see whether the diminished T cell 
reactivity is of genetic origin. 
(4) Vascular factors 
In this project he roles of blood pressure and other 
risk factors as determinants of vascular dementia will 
be investigated. The aim is to develop a risk function 
which can be used to reach decisions concerning the 
treatment of mild or moderate hypertension i  order to 
prevent vascular dementia. The risk function will be 
composed of variables measured uring the Rotterdam 
Elderly Study, including blood pressure (isolated 
systolic hypertension), history of cerebrovascular 
disease (with emphasis on TIA's)  and other 
cardiovascular diseases, major cardiovascular risk 
factors (serum lipids, smoking habits) and ECG 
characteristics. The risk function will be based on a 
comparison of these variables among patients with 
vascular dementia nd control subjects. This study may 
be seen as preparation for an intervention study of the 
treatment of hypertension toprevent vascular dementia. 
(5) White matter brain lesions 
An association between cognitive impairment, 
white matter lesions in the brain, and cardiovascular 
disease has long been suspected for a subgroup of 
patients uffering from dementia. Recent studies with 
MRI have indicated that the cerebral consequences of a 
high cardiovascular risk may be even more important 
and widespread. In this study, the prevalence of white 
matter lesions will be assessed in a random sample 
drawn from the study cohort as well as a group of 
participants at high risk for cardiovascular disease and 
patients with cognitive impairment. This will allow the 
identif ication and quantif ication of cognit ive 
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dysfunction due to atherosclerotic vessel disease, and 
the contribution of "classical" and hemostatic risk 
factors can be assessed. 
2.2. Cardiovascular diseases 
2.2.1. Introduction 
The objective of the study of cardiovascular 
diseases in the Rotterdam Elderly Study is to clarify the 
determinants of cardiovascular disease in an ageing 
population. In this study, special emphasis will be 
placed on the contribution of thrombogenesis and blood 
vessel wall changes. In the following paragraphs we 
will briefly discuss the research questions, background 
and rationale, and design of the study. In addition, a 
description of the hemostatic parameters measured 
during the study will be given. 
2.2.2. Research questions 
Primary 
1. What are the determinants of the occurrence and 
progression of atherosclerotic vessel disease and 
the development of cardiovascular disease, and 
what is the role of disturbances in hemostatic 
function? 
2. Is progression of vascular atherosclerotic lesions in 
asymptomatic elderly patients a prelude to 
cardiovascular events? 
Secondary 
1. What are the prevalence, incidence and 
determinants ofaneurysms of the abdominal aorta? 
2. Are risk factors for cardiovascular disease, in 
particular high blood pressure, associated with 
cognitive impairment in the elderly and the 
occurrence of lesions of white brain matter? 
3. What is the importance of raised insulin levels in 
the development of cardiovascular and 
cerebrovascular disease, and what are its 
determinants? 
4. What are the determinants of deep venous 
thrombosis in the elderly, and what is the role of 
genetic or acquired changes in hemostatic 
function? 
5. Is it possible to develop arisk function for vascular 
dementia that could be used to design subsequent 
intervention studies? 
6. What is the association between social and 
economic status, social support and the 
development of cardiovascular disease in the 
elderly? 
2.2.3. Background and rationale 
Introduction 
In the next decades, an increasing number of 
elderly people will become severely handicapped ordie 
as a consequence of cardiovascular nd cerebrovascular 
disease (79, 97). In addition to the well-known 
consequences of atherosclerotic vessel disease; 
myocardial infarction and stroke, the impact of other 
consequences of atherosclerotic circulatory 
disturbances ( uch as peripheral artery disease, aortic 
aneurysms, congestive heart failure, and vascular 
dementia) on the quality of life for the elderly is 
becoming increasingly apparent (27, 33). 
Primary research questions 
In the search to find factors which would favorably 
influence the morbidity and mortality due to 
cardiovascular disease in the elderly, factors which lead 
to atherosclerosis are exceedingly important. It is the 
rule rather than the exception that blood vessels in the 
population over 50 years of age are to a greater or lesser 
extent affected by atherosclerosis. There is growing 
agreement that an answer is needed to the question of 
which factors in the presence of atherosclerosis will 
lead to symptoms of cardiovascular disease. In this 
respect, a distinction can be made between factors 
promoting the vulnerability of the myocardium or the 
brain to ischemic attacks and factors that trigger 
significant occlusion of vessels already affected by 
atherosclerotic changes (33, 74). Findings from a 
number of studies point to hemostatic factors as 
candidates for the latter category (21, 88) There are 
indications that platelet aggregation and increased 
activity of a number of clotting factors, reduced 
effectiveness of clotting inhibiting plasma proteins, and 
the fibrinolytic system contribute to atherosclerotic and 
thrombo-embolic complications (25, 52, 64, 65, 104, 
105, 107). As an example, in a comparison of Japanese 
men living in different countries with different 
cardiovascular disease rates, different mean levels of 
coagulation factors appeared to explain part of the 
differences in cardiovascular disease, independent of 
other cardiovascular risk indicators (48). These 
findings are supported by reports about he efficacy of 
oral anticoagulants, prostaglandin inhibitors and 
platelet aggregation inhibitors in the secondary 
prevention of coronary heart disease and 
cerebrovascular accidents and in patients with unstable 
angina pectoris (4, 1 t, 59, 76, 92). In addition; recent 
findings on the efficacy and risks of aspirin in the 
prevention of first myocardial infarction demonstrate 
the importance of the ability to predict who will and 
who will not profit from such preventive measures (77, 
97 ). Disturbances in hemostatic activity which are risk 
factors for thrombosis increase with ageing (63). 
Understanding of the part played by hemostatic 
disturbances in the initiation and progression of 
vascular lesions and overt cardiovascular disease is one 
of the main objectives of the cardiovascular p oject of 
the Rotterdam Elderly Study. The investigation of the 
influence of hemostatic factors on atherosclerosis and 
its morbid sequelae cannot be separated from studies of 
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other determinants of cardiovascular disease. 
Moreover, in view of the fact that atherosclerotic 
changes most probably promote coagulation, it is 
necessary to investigate the association between these 
factors in a prospective study (40). 
The most important change in the blood vessel wall 
at the initiation of cardiovascular diseases is thought o 
be the formation of atherosclerotic plaques (75, 88). An 
increasing stiffness of the blood vessel wall with age 
and with certain risk factors has been reported, even in 
otherwise asymptomatic people (51). More recently, 
emphasis has been put on arterial wall thickness as a 
marker of general ized atherosclerosis and 
cardiovascular risk. The sequence of the development 
of generalized vessel wall changes and localized 
atherosclerotic blood vessel lesions as well as the 
interaction with hemostatic and other cardiovascular 
risk factors is as yet unknown. The development of 
reliable non-invasive methods for the imaging of blood 
vessels enables us to study a large number of 
asymptomatic subjects (9, 26, 68, 90). The proposed 
study offers the possibility to clarify the interaction of 
hemostasis,  blood vessel wall changes and 
cardiovascular disease in ageing people. In the 
Rotterdam Elderly Study state-of-the-art imaging of the 
carotid arteries is accompanied by extensive assessment 
of atherosclerotic involvement in other parts of the 
cardiovascular system. 
Hypertrophy and dilatation of the myocardium are 
known consequences of long- standing hypertension 
and chronic myocardial ischemia. Yet, recent findings 
suggest hat changes in the dimensions of the left 
ventricle may be  not only a consequence of 
hypertension and coronary artery disease but also a 
potent independent marker of subsequent risk for 
myocardial infarction and other cardiovascular events 
(57, 58). As part of the Rotterdam Elderly Study 
cardiovascular project, the dimensions of the 
myocardium wi l l  be measured by means of 
echocardiography. In addition, the more conventional 
approach of assessment of left ventricular hypertrophy 
by electrocardiography will be applied. Together with 
imaging of the carotid artery, this will enable us 
to study the relative contributions of risk factors 
for cardiovascular disease to myocardial and ca- 
rotid damage and their respective risks for future 
morbidityl 
The disease parameters and putative determinants 
selected for the cardiovascular p oject of the Rotterdam 
Elderly Study reflect he general objective of the study: 
to clarify the potential for preventive measures against 
cardiovascular risk in the elderly. 
:incidence and determinants of vessel wall changes in 
the elderly and their association with symptomatic 
cardiovascular disease (70). In addition, the value of 
various diagnostic strategies in the detection and 
management of aortic aneurysms will be evaluated 
from a decision analytic perspective (78, 103). 
(2) White matter brain lesions 
An association between cognitive impairment, 
white matter lesions in the brain, and cardiovascular 
disease has long been suspected for a subgroup of 
patients suffering from dementia (7, 23, 47). Recent 
studies with nuclear magnetic resonance imaging have 
indicated that the cerebral consequences of the 
cardiovascular risk status may be much more important 
and widespread than previously thought (54). In the 
proposed study, the prevalence of white matter lesions 
will be assessed in a random sample drawn from the 
Rotterdam Elderly Study cohort as well as a group of 
participants at high risk for cardiovascular disease and 
patients with cognitive impairment. This will lead to the 
quantif ication of cogni t ive  dysfunction as a 
consequence of atherosclerotic vessel disease and the 
contribution of "classical" and hemostatic risk factors 
to the disorder. 
(3) Diabetes mellitus 
Diabetes is one ofthe most important risk factors 
for cardiovascular disease (73). The incidence and 
prevalence of diabetes are rising in Westernized 
societies (53), and its burden in terms of economic 
consequences amounts to more than one third of the 
total costs of the health effects of cigarette smoking 
(46). The progression of atherosclerosis in diabetic 
patients is only partly preventable by controlling 
glucose metabolism (85). It has been suggested that 
glucose intolerance and other cardiovascular risk 
factors (e.g. hypertension, hyperlipidemia), and 
perhaps the development of atherosclerosis it elf, may 
be different reflections of the same metabolic or 
enzymatic disturbance l ading to insulin resistance and 
raised insulin levels (81, 95). In the proposed study the 
prevalence of diagnosed iabetes mellitus and non- 
clinical glucose intolerance, as well as raised plasma 
insulin levels, will be assessed and their association 
with vascular disease :andl the "classieai" and 
hemostatic risk factors e'xpiored. In addition, the 
incidence of raised insulin levels, glucose iniolerance, 
and the determinants of progresslo n of atherosclerotic 
vessel disease in diabetes will be evaluated uring the 
follow-up period. 
2.2.4. Specific projects 
(1) Aneurysms of the abdominal aorta 
Aneurysms of the abdominal aorta will be studied 
as part of the general ssessment of the prevalence, 
(4) Deep venous thrombosis 
The incidence of deep venous thrombosis rises 
with age, in particular after age 50, and is associated 
with substantial morbidity and mortality in the elderly 
(10, 17). In the Rotterdam Elderly Study, all 
symptomatic ases of deep venous thrombosis and 
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pulmonary embolism occurring during the follow-up 
period will be monitored. These patients will be 
compared with a reference group randomly drawn from 
the same population. The comparison will include 
hemostatic factors (e.g. protein S, protein C and 
antithrombin III) in frozen plasma samples obtained 
from the participants prior to the thrombosis and 
acquired risk factors (trauma, surgery, immobility) 
prior to the time of the event. 
(5) Vascular factors in dementia 
In this project he role of blood pressure and other 
risk factors as determinants of vascular dementia will 
be investigated. The aim of this project is to develop a
risk function which may be used for decisions 
concerning the treatment of mild to moderate 
hypertension in order to prevent vascular dementia. The 
risk function will be composed of variables measured in
the Rotterdam Elderly Study and easily assessed in 
clinical practice, including blood pressure (isolated 
systolic hypertension), history of cerebrovascular 
disease (with emphasis on TIA's) and other 
cardiovascular diseases, major cardiovascular risk 
factors (serum lipids, smoking habits) and ECG 
characteristics. The risk function will be derived from a 
comparison of these variables among patients with 
vascular dementia nd control subjects. This project 
should provide the basis for an intervention study on 
treatment ofhypertension to prevent vascular dementia. 
(6) Socio-economic status and cardiovascular disease 
The objective of this project is to assess differences 
in cardiovascular morbidity and mortality between 
groups of different socio-economic status. The extent to 
which these differences can be explained by differences 
in cardiovascular risk factors and the modifying 
importance of social support is also examined. The 
study will be conducted in collaboration with the 
Rotterdam Municipal Health Authorities. 
2.2.5. Study design and methods 
Design 
The Rotterdam Elderly Study is a longitudinal 
study of determinants of the occurrence of 
cardiovascular disease in an elderly population. A 
significant proportion of the research questions may be 
answered by means of the nested-case-control 
approach. The study is a prospective follow-up study of 
a cohort of 11,850 people, aged 55 years and over. In a 
period of five years the participants will be examined 
twice. During this period, and thereafter, the incidence 
of cardiovascular diseases and deaths will be assessed. 
In the first part of the study the interplay between 
parameters of hemostasis and characteristics of blood 
vessels and the myocardium will be examined. In this 
phase, demonstrable atherosclerotic lesions as well as 
the vessel wall thickness and flow profiles of the carotid 
arteries will be registered. At the same time the well- 
known "classic" risk indicators will be registered, so 
that he relative contribution ofthese diverse factors can 
be assessed. The latter include serum lipids, blood 
pressure, left ventricular mass, electrocardiographic 
abnormalities, glucose intolerance and insulin levels. In 
addition, the presence of aneurysmatic dilatation of the 
abdominal aorta, blood pressure changes across the 
peripheral arteries and the mental and cognitive 
performance of the participants will be measured. At 
the second examination about 2.5 years later all 
baseline parameters, including the blood vessel 
characteristics, will be re-examined. The role of 
hemostatic and other factors in the development and 
progression of atherosclerotic blood vessel and cardiac 
disease can then be assessed. During a follow-up eriod 
of at least five years the incidence of cardiovascular 
illness and death will be monitored. In this way it will 
be possible to study the risk for cardiovascular illnesses 
attributable todisturbances in hemostasis, blood vessel 
wall abnormalities and progression of atherosclerosis 
and to relate these factors to other isk factors. 
The proposed study focusses on factors that explain 
the incidence of seriously handicapping forms of 
cardiovascular illnesses, such asangina pectoris, heart 
failure, stroke, intermittent claudication and "multi- 
infarct" dementia. Using the findings of the first and 
second phases of the study it will be possible to select 
groups which, on the basis of coagulation 
characteristics and/or blood vessel abnormalities, 
exhibit a higher than expected incidence of 
cardiovascular illness. These groups can then be used 
for yet to be determined a ditional studies on the effect 
of preventive measures. 
Methods 
The study forms a part of the Rotterdam Elderly 
Study and will be carried out among 4,570 men and 
7,280 women aged 55 years and over, who reside in the 
district Ommoord of Rotterdam. During the study 
period every participant will be visited at home and 
examined at the research center, twice, the two 
examination rounds being 2.5 years apart. A venous 
blood sample will be taken for general biochemical 
determinations and the characterization of coagulation. 
Particular care will be taken to prepare plasma samples 
for storage at -70 ° Celcius, to allow future 
determinations of selected hemostatic parameters in 
case-control studies. 
2.2.6 Measurements 
The following data will be obtained at the home 
interview and clinical examination: 
* Interview/questionnaires: medical history, drug 
hi story, family history, diet (semi-quantitative food 
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frequency), cardiovascular illnesses (modified 
Rose questionnaire), Geriatric Mental State 
Examination, Mini Mental State Examination, 
physical activity, social and economic status, 
quality of life; 
* Physical examination (limited); 
* Anthropometry: height, body weight, hip to waist 
ratio (body fat distribution) 
* Blood pressure (sitting and orthostatic response); 
* ECG, resting (12 leads); 
* Vascular and cardiac measurements: Ultrasonic 
Duplex scanning of carotid arteries, Doppler-blood 
pressure readings (dorsalis pedis artery, posterior 
tibial artery), 2-D echographic measurement of 
abdominal aortic dimensions, M-mode 
echocardiographic assessment of left ventricular 
wall mass and left ventricular dimensions; 
* Glucose tolerance test; 
* Venous blood sample. 
2.2.7. Hemostat i c  determinat ions :  ra t iona le  and 
table of  measurements  
The table of measurements lists the factors to be 
studied under five headings (Table 2). The selection of 
TABLE 2. - The table indicates the hemostatic 
determinations to be performed in the Rotterdam 
Elderly Study. 
Name Name 
I. Platelets III. 
number A 
Beta-TG A 
PlateletFIV B 
II. Coagulation 
APTT B 
fibrinogen A 
FF A ~ 
FVIIC A 
F VII Ag B IV. 
F VIII C A 
F VIII Ag B 
F II Ag B 
FXAg B 
VWF Ag B 
FPA B 
V. 
Anticoagulants 
AT-III A 
Pr0t. C Ag B 
Prot. C Act A 
Prot. S Agt B 
EPI B 
Alpha- 1 -AT C 
HC-II C 
Thrombomodulin C 
Fibrinolysis 
Plasminogen B 
t-PA Act B 
t-PA Ag B 
PAI Act B 
Alpha-2-AP B 
Blood vessel wall protein 
PGP C 
A = measured in total group; A 1 = in participants on oral 
anticoagulant drugs only 
B = prepared and stored at -70 degr. celsius for future analyses 
in selected cases and controls 
C = prepared and stored at -70 degr. celsius; future analyses is 
considered 
factors was determined by the fol lowing 
considerations. The most important consideration for 
selection isthe possibility that a new and important risk 
indicator will be found, preferably one that is amenable 
to prevention. A second aspect is the need to confirm 
conclusions of previously published studies. Finally, 
there are the special interests of the researchers 
involved in this project. On the basis of these 
considerations, it was decided that the major topics 
would be coagulation (II), especially factors that 
promote and inhibit coagulation, and blood vessel wall 
protein (V). In addition, the importance of fibrinolysis 
was recognized; therefore samples for measurement of 
fibrinolytic factors will be stored. However, the 
importance of these measurements needs further 
assessment. 
In category I the platelet count will be determined 
for all participants. Platelet aggregation studies are 
labor intensive and require fresh blood specimens 
which presents great logistic problems (63). However, 
platelet activation may be an important determinant of 
subsequent cardiovascular events and progression of 
vessel wall abnormalities. Therefore, investigation of
the secretion products of blood platelets has been 
chosen; at present only beta-thromboglobulin (Beta- 
TG) is measured inall participants. Additional material 
will be prepared and frozen for further determinations, 
in particular within the framework of future case- 
control studies. 
Category II includes a number of factors which 
previous tudies have indicated to be involved in the 
development of cardiovascular disease. Amongst these 
are fibrinogen and factor VII (52, 64, 65, 104, 105, 
107). A role for factor VIII has been suggested by the 
findings of Rosendaal et al. that surprisingly few 
patients with hemophilia A die of a myocardial 
infarction (2). The Von Willebrand Factor (VWF) 
could be of importance because pigs lacking this 
protein are resistant to the development of 
atherosclerosis (30, 72). Factors II and X have been 
included because they are essential indices for the 
estimation of proteins C and S. The APTT provides 
information both when shortened (high concentration 
of intrinsic Clotting factors) and when prolonged (lupus 
anticoagulants). Prothrombin time (PT) is measured 
selectively in subjects on anticoagulant therapy. To 
gain an impression of thrombolytic activity in the 
circulation fibrinogen peptide A (FPA) is measured. 
Interesting findings are expected for category III. 
These determinations will mainly be performed on the 
basis of case-control studies of a limited number of 
subjects, notably patients suffering from cardiovascular 
events during the follow-up period and controls. The 
importance ofthe complex system of interacting factors 
that counteracts he coagulation cascade during the 
initiation and progression ofcardiovascular disease has 
not yet been the subject of investigation. Studies of 
patients with venous thrombosis have suggested that 
the protein C - protein S thrombolytic system is an 
important risk factor for cardiovascular disease, while a 
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recent communication from Von Felten (personal 
communication) and experience in Leiden with 40 
atherosclerotic patients point to the possible role of 
protein S. The extrinsic pathway inhibitor (EPI), alpha- 
1 antitrypsin (alpha-l-AT) and heparin cofactor II (HC- 
II) are recent additions to the regulating system of 
thrombin formation. It is thus recommended that these 
components be measured if this is possible. 
Category IV comprises various parameters of 
fibrinolysis. Recently, in angina pectoris PAI was 
found to be positively correlated with triglycerides as 
well as with insulin (36, 50). In a prospective study PAl 
was associated with the incidence of reinfarction. 
Extensive ongoing prospective studies (NIH ARIC and 
ECAT AP) on cardiovascular diseases also include t- 
PA and PAI assays (100, 101). Inclusion of some 
fibrinolysis assays in the study will be considered at a 
later date, the stored plasma samples can then be 
assessed. 
Finally, the discovery of Plaque GLA-protein 
(PGP) offers the interesting possibility of a completely 
new direction for research on the development and 
prevention of atherosclerosis. In Maastricht, research 
activities focus on vitamin K-dependent proteins which 
include not only the well-known coagulation proteins 
(II, VII, IX, X) and coagulation i hibitors (proteins C 
and S) but also osteocalcin and PGP that have been 
isolated from atherosclerotic plaques. Vitamin K- 
dependent proteins have the property of binding 
calcium and it is not unlikely that PGP has a part to play 
in the development of atherosclerosis. Because of these 
considerations, the opportunity ostudy this protein was 
included in this project. 
2.3. Locomotor diseases 
2.3.1. Introduction 
Osteoarthritis and osteoporosis are the locomotor 
disorders that threaten in particular the mobility and 
independence of the elderly. Investigation of etiologic 
determinants is most promising for osteoporosis. In this 
section the study of osteoporosis and osteoarthritis is 
described. 
femur. Baseline clinical data will be collected by 
interview and physical examination. Duration of 
follow-up will be 2.5 years. Then, baseline bone 
imaging procedures will be repeated. Fracture status 
will be recorded during follow-up. As a result of the 
study it should be possible to identify one or more 
groups with a high risk for age-related osteoporosis, in 
order to investigate fracture-risk reduction by specific 
interventions in randomized controlled trials. The 
osteoporosis project will also contribute regional data 
to a comparative study of geographical variations in 
osteoporosis prevalence between European 
populations. 
2.3.2.2. Research questions 
Primary 
1. What is the incidence rate ratio and rate difference 
for vertebral and hip fractures in men and women 
with low versus high initial bone mineral 
parameters? 
2. What are the determinants of vertebral and 
proximal femur fractures? 
3. What are the determinants of bone mineral density 
in elderly men and women? 
Secondary 
1. Is it possible to construct a risk function for 
vertebral and proximal femur fractures, which can 
be used as a guide for intervention? 
2. What is the association between bone mineral 
density and vertebral crusl~ fractures and a history 
of limb fractures? 
3. What are the determinants of the rate of bone 
mineral loss at spinal and proximal femur sites in 
elderly men and women? 
4. Is the rate of bone mineral oss at one location 
(vertebrae) associated with that at another 
(proximal femur)? 
5. What is the clinical significance ofdiscrepancies in 
the outcome of the different bone mineral density 
assessments? 
2.3.2. Osteoporosis 2.3.2.3. Rationale 
2.3.2.1. Scope of research 
The osteoporosis research project aims to identify 
determinants of the occurrence of hip and spinal 
fractures, A prospective follow-up study will be carried 
out in men and women, aged 55 years and over. X-ray 
films of the thoracolumbar spine and pelvis (hips) will 
be taken at entry, simultaneously with bone mineral 
density measurements at the sites of the lumbar 
vertebrae L I --~ L IV and, one-sided, the proximal 
One of the leading causes of fractures in the elderly 
is osteoporosis. Osteoporosis is defined as a decrease in
bone mineral content leading to non-traumatic 
fractures. It is a serious health problem as far as the 
number and severity of cases is concerned and in terms 
of health care expenditures (15, 20, 83). Women over 
80 years of age exhibit a 15 to 20% higher mortality in 
the first year after hip fracture (20). The prevalence of 
vertebral fractures and hospital admissions for a 
proximal femur fracture increase markedly with age. 
Moreover, the age-adjusted incidence rates for hip 
413 
Hofman A. et aL Eur. J. Epidemiol. 
fractures show an increase in some European countries, 
including the U.K. and the Netherlands (8, 44). Women 
of all ages run a higher isk for osteoporotic fractures 
than men. 
The regulation of bone tissue mass and structure 
involves the coupled actions of osteoclastic and 
osteoblastic ceils; the dynamic equilibrium between 
resorption and new bone formation is controlled by 
PTH and steroid hormones (80). Bone mass at a certain 
point in life is the net result of the peak bone mass 
reached in the third decade and the subsequent 
cumulative loss. Morphology of bone tissue depends on 
its anatomic localization. In the shafts of the long bones 
cortical bone predominates; in vertebrae, pelvis and 
other flat bones trabecular (or cancellous) bone is 
found, surrounded by a cortex. Different rates of bone 
mineral oss have been described for the cortical and 
trabecular types of bone in both men and women; 
therefore the processes of remodelling and breakdown 
of bone tissue are not uniform throughout the body ( 60, 
66, 71). Moreover, the phase of accelerated loss in 
postmenopausal women is mainly one of cancellous 
bone loss (45, 60). These observations gave rise to the 
concept of dividing osteoporosis nto type I: post- 
menopausal (affecting trabecular bone) and type II: 
age-related (predominantly loss of cortical bone) (82). 
Fractures at a site dominated by cortical or cancellous 
bone morphology can therefore be related to type I or 
type II osteoporosis. Recently, however, this 
classification system has been questioned because it 
appeared difficult o relate fracture occurrence patterns 
with the distribution f bone mineral mass and the 
unexpected low frequency of multiple common-type 
fractures in individual patients (19). In this respect, the 
prospective study of localization-specific fractures in 
relation to baseline bone mineral density at these spots 
will be most informative. The study of bone mineral 
dynamics at the lumbar spine and proximal femur in 
men and women will lead to new hypotheses on the 
contribution ofosteoporosis tothe etiology of fractures. 
Osteoporosis  an important determinant of age- 
related hip fractures, although not necessarily either the 
only or a sufficient one (67). Attention has been called 
to intrinsic bone factors uch as fatigue and trabecular 
disconnection as an explanation for bone fragility, apart 
from simply the reduction in bone mass (38). 
Furthermore, extraneous factors such as cognitive 
function or drug use must be taken into account as a 
cause of falls and thus, for example, of hip fractures. In 
the Rotterdam Elderly Study the most important 
determinants of fall accidents are investigated in detail. 
Bone mineral density can thus be studied in relation to 
other determinants of fractures. 
More than one bone mineral measurement 
technique applicable at either the axial or peripheral 
skeleton is in use today. There is no obvious best choice 
(93); even worse, correlations between measurements 
are disappointing (5, 84). The optimal bone mineral 
measurement technique for this population study needs 
to be a safe, quick, non-invasive method with high 
precision and reproducibility over time. Dual Energy 
X-ray Absorptiometry (DEXA) promises to be the most 
appropriate chnique. The standard software vailable 
allows us to assess bone mineral content and bone 
mineral density of lumbar spine and proximal femur in 
most cases with reasonable confidence. In this protocol, 
DEXA measurements of lumbar spine and a unilateral 
proximal femur will be carried out. Phalangeal 
radiodensitometry, i.e. bone mineral quantification 
based on estimates of the bone mineral density of cross- 
sections of one phalangeal bone using the hand X-ray 
image, is an additional assessment (102). 
Many questions remain about he prevention, early 
diagnosis and treatment of osteoporosis. Identification 
of risk factors for fractures and the construction of a 
fracture risk-function for selecting of high-risk groups 
within the elderly population is challenging, especially 
with a view to planning future clinical trials. This 
prospective study on the dynamics of bone mineral 
content at different skeletal sites will lead to new 
advances in our understanding of the etiologic role of 
well-established and putative determinants of bone 
mass. Moreover, the study will help to pave the way for 
the exploration of potential preventive strategies aimed 
at osteoporotic fractures at their clinically most 
important localisations: proximal femur and vertebrae. 
2.3.2.4. Study design 
Population 
The osteoporosis research project is incorporated 
in the Rotterdam Elderly Study. This is a prospective 
follow-up study on the incidence and determinants of 
geriatric diseases in the general population. The initial 
baseline part of the study consists of an interview at the 
participant's home carried out by a (trained) research 
assistant, followed by a visit to the field center where 
the medical examinations will be performed. 
Cross-sectional study 
In the cross-sectional part of the study, the 
determinants of bone mineral density will be 
investigated. Radiographic evidence of vertebral 
fractures, as well as a history of limb fractures, will be 
studied in relation to their respective determinants. 
Study endpoints (follow-up study) 
(1) Fracture of the hip. 
Information on cases will be obtained from the 
health care system. Details on fracture site will be 
described according to available X-ray examinations. 
The estimated annual number of fractures of the hip for 
our study population is40-50 for women and 10-15 for 
men.  
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(2) Vertebral fractures. 
Data will be obtained by comparing individual 
baseline and follow-up X-ray examinations. Incident 
cases of new vertebral fractures in women over 70 years 
of age are estimated at 1% per year. 
(3) Bone mineral dynamics. 
Data on individual changes in bone mineral content * 
will be obtained by comparing individual baseline and 
follow-up DEXA bone mineral density measurements 
of the lumbar vertebrea 2-4 and the proximal part of one * 
femur. 
ionized calcium, total calcium, sodium, potassium, 
glucose, creatinine, alkaline phosphatase, gamma 
glutaryl transferase, albumin, 25 (OH) 
cholecalciferol, 1,25 (OI-t) 2 cholecalciferol 
(subgroup), estrogen (subgroup), testosterone 
(subgroup), sex-hormone binding globulin 
(subgroup), parathormone (subgroup), thyroid 
stimulating hormone, osteocalcin (subgroup) 
clinical chemistry in urine: 
sodium, calcium, (OH)proline (subgroup), 
creatinine 
hematology: erythrocyte sedimentation rate, 
hemoglobin. 
(4) Cause-specific death. 
Notification of death will be obtained from the 
municipal council and causes of death from the general 
practitioners. 
2.3.2.5. Measurements 
(1) History 
* age, gender 
* medical history: menarcheal ge, menopausal ge, 
oophorectomy, pharmacotherapy: current 
prescribed and non-prescribed drug use, previous 
use of estrogens, prednisone and antihypertensives, 
limb fractures in the past 5 years, diabetes mellitus, 
nephrolithiasis, rachitis, arthritis, cardiovascular 
disease, dementia, thyroid disease, smoking history 
* dietary history: total calcium intake, 
phosphate,total c ory intake, alcohol consumption 
* physical activity 
* sunlight exposure 
* family history of hip fracture. 
(2) Physical examination 
* anthropometry: body height, sitting height, body 
weight, hip/waist ratio 
* sphygmomanometry: sitting blood pressure, 
postural blood pressure change 
* additional: electrocardiography, neurologic 
examination, visual acuity 
(3) Bone imaging 
* radiography: lateral films of the thoracic and 
lumbar spine (Th IV --+ L V); pelvis AP; hands and 
wrists 
* bone mineral densitometry: DEXA of the lumbar 
spine (L II --~ L IV) and one proximal femur; 
phalangeal radiodensitometry. 
To study changes over time, radiography and bone 
densitometry will be repeated three years after 
baseline. 
(4) Laboratory assessments 
* clinical chemistry and hormones in serum: 
2.3.2.6. Specific projects 
(1) Prevalence of vertebral fractures 
The study of the prevalence of vertebral 
osteoporotic fractures and their determinants will also 
be part of a collaborative project of the European 
Community. The possible causes of differences in 
regional prevalence figures will be investigated using a 
comparable methodology under the auspices of the 
European Vertebral Osteoporosis Study. 
(2) Intervention study of vitamin D 
Deficiency of vitamin D is common in the elderly. 
Due to decreased calcium absorption and secondary 
hyperparathyroidism, this may lead to bone loss. In a 
randomized controlled trial the effect of vitamin D 
suppletion in septenarians will be studied. The 
incidence rate of hip fractures in the elderly over 70 
years of age is high and still increasing. The primary 
endpoint for this subproject therefore is hip fracture. 
(3) Intervention study of calcitonin 
The recently available formulation for intranasal 
application makes calcitonin one of the most promising 
pharmacotherapeutics for primary and secondary 
prevention of osteoporotic fractures. The efficacy in 
bone mineral conservation and the relative safety of the 
drug potentially allow application on a broad scale. 
Once a high-risk group for the development of 
osteoporotic fractures can be defined within the 
population, this innovative calcitonin formulation 
deserves formal testing. 
2.3.3. Osteoarthritis 
The objective of this study is to investigate the 
determinants of disability in the elderly in relation to the 
high prevalence of radiographic osteoarthritis. 
Attention will be focussed on hip and knee 
abnormalities ince they are the major causes of 
mobility handicaps. The concepts impairment, 
disability and handicap used here are those defined by 
the WHO (66). 
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2.3.3.1. Research questions 
1. What are the determinants of the occurrence or 
progression of disabilities? 
2. What proportion of disabilities is associated with 
signs of radiographic osteoarthritis? 
3. What are the determinants of disabilities, given that 
signs of radiographic osteoarthritis are present? 
2.3.3.2. Rationale 
Epidemiologic surveys in the past have 
demonstrated that signs of radiographic osteoarthritis 
are one of the most prevalent abnormalities among the 
elderly (14, 89). The discrepancies between 
radiographic signs, physical findings and symptoms are 
striking (13). Little is known about the prognosis of 
degenerative joint disease. It is clear that severe arthritic 
deformities are associated to a certain extent with 
disability and limitation of the activities of daily living. 
In view of the ageing population it is worthwhile to 
investigate the quantity and severity of disabilities 
associated with degenerative joint diseases. Knowledge 
of the determinants of disability and progression of 
disability may lead the way to future intervention 
programs. Understanding the determinants of disability 
or progression in the presence of radiographic 
osteoarthritis may result in preventive strategies to 
modify the natural history of osteoarthritis. 
2.3.3.3. Measurements 
* Medical history, family history 
* Present health status 
* Physical examination, including knee and hip 
functions 
* Assessment ofselected activities of daily living by 
trained observers 
* Radiography: X-ray films of hips, knees and 
hand/wrist 
* Laboratory tests 
2.4. Ophthalmologic diseases 
2.4.1. Introduction 
The four most common age-related causes of 
blindness in the Western world are age-related macular 
degeneration (AMD), cataract, diabetic retinopathy and 
glaucoma. After cataract extraction, vision is usually 
restored, but this is often not the case after treatment of
the other three disorders. This is true especially for 
AMD, the major blinding disorder of old age. 
Therefore, it is essential to gain more insight into the 
etiology of AMD by studying its prevalence, incidence 
and determinants. According to blind registration data, 
AMD is the most common cause of blindness ill the 
elderly in the United Kingdom (1, 31). In a population- 
based study in the US (55), AMD came second to 
cataract while it ranked first in a similar U.K. study 
(32). There are considerable differences in the 
estimations of blindness derived from blindness 
registries and those based on population studies. 
Moreover, in the latter the number of non-responders 
varied from 21.9% (32) to 33% (55) and there is 
evidence that the percentage ofblind people was much 
higher among these non-responders than among the 
responders (24, 32, 55). 
In The Netherlands such a population-based study 
has never been performed. The Age-Related Eye 
Analysis (AREA) Study will start as a prevalence study 
in connection with the Rotterdam Elderly Study. The 
data from the Rotterdam Elderly Study will be used to 
search for determinants with a possible etiologic 
significance for the previously mentioned eye 
disorders. The emphasis will be on AMD and glaucoma 
since these are the two main causes of visual 
impairment in the elderly. At a later stage a follow-up 
study is scheduled to assess the incidence of these 
disorders, investigate putative risk factors and perform 
intervention studies. 
In AREA emphasis will be on AMD and glaucoma, 
since they are the main causes of visual impairment in
the elderly in the Western world and also because their 
etiology is least known. The prevalences of glaucoma 
and AMD show a steep but non-parallel rise with 
advancing age from 1.4% and 4.0% to 2.9% and 15.4%, 
respectively (55). For this reason as well as the need for 
sufficiently large subgroups to be able to study risk 
factors it was decided that all 11,850 potential 
participants should be examined. 
2.4.2. Scope of the AREA study 
The ultimate goal is to prevent he occurrence of 
severe invalidating eye disorders in the elderly. AREA 
focusses on the following points: 
* Determination f prevalence (and in a later stage 
incidence) of major eye disorders causing visual 
impairment. 
* Search for risk factors, especially for AMD and 
(low tension) glaucoma. 
* Comparison with similar studies in the past and a 
simultaneous study in the London Inner City. 
* Identification ofsubgroups for further intervention 
studies of glaucoma nd AMD. 
2.4.3. Specific questions of AREA 
1. Prevalence and incidence 
1.1 What is the prevalence and incidence of AMD in 
the elderly? 
1.2 What is the prevalence and incidence of glaucoma 
in the elderly? 
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1.3 What percentage ofthe aged population isvisually 
handicapped or blind, according to the WHO 
criteria? 
2. Study of putative risk factors 
2.1 Are cardiovascular (atherosclerotic vessel disease, 
hypertension, abnormalities in lipid metabolism 
and hematological nd coagulation disorders) and 
biochemical abnormalities or a positive family 
history associated with simple glaucoma, low- 
tension glaucoma or AMD? 
2.2 Is cumulative lifetime light exposure or decreased 
iris or fundus pigmentation associated with AMD? 
2.4.4. Rationale 
Not much is known about the etiology of age, 
related macular degeneration (AMD). As a rule AMD 
is preceded by the formation of drusen in the macula. 
Drusen are thought to be accumulations of degenerative 
cell material from the photoreceptors. Drusen may be 
inherited in an autosomal dominant way but are often 
sporadic. Exposure to light, the presence of blue eyes, 
abnormal serum zinc levels and abnormalities in skin 
elastin have also been mentioned as predisposing 
factors for AMD (24). 
For the purpose of this study glaucoma may be 
divided into primary open angle (POAG) and closed 
angle glaucoma. POAG can be subdivided into two 
groups, one with high (POAGH) and the other with low 
(POAGL) eye pressure. Both the pathogenesis of 
POAGH and POAGL and the prevalence of POAGL 
are unknown (56). POAGH may be inherited as an 
autosomal dominant disorder. However, there are also 
many sporadic ases. Abnormalities in the constituents 
of the trabecular meshwork in the chamber angle of the 
eye have been pointed out as a possible cause of POAG 
but the etiology of these abnormalities i unknown. 
Lately cardiovascular disorders have been suggested as 
a main etiologic factor, especially for POAGL. 
2.4.5. Study design 
A total of 11,850 people, 55 years and over and 
residing in one city district of Rotterdam (Ommoord), 
will be invited to participate (see chapter 1). They will 
be visited in their homes by an investigator to answer 
questions that will be entered into a portable computer. 
At a later stage these people will be examined at the 
Rotterdam Elderly Study field center. The ophthalmic 
examination will be performed by ophthalmology 
residents under supervision of ophthalmologists. 
According to the schedule 20 patients will be seen 
daily; the first part of the study will take 2.5 years. 'If 
further diagnostic procedures or ophthalmological 
treatment is indicated, patients will be refeffed to the 
Institute of Ophthalmology of the Erasmus University. 
Rotterdam. As a last step, data will be analyzed and 
cross-linked with other data from the Rotterdam 
Elderly Study. The study is scheduled to be repeated 
after 2.5 years in order to calculate incidence rates. 
2.4.6. Measurements 
* Refraction: autorefraction, lensometry, subjective 
refraction, best corrected visual acuity; 
* Slit lamp biomicroscopy: routine slit lamp 
examination, depth of the anterior chamber angle; 
* Keratometry; 
* Applanafion tonometry; 
* Perimetry: semi-automatic esting; 
* Funduscopy: direct and indirect ophthalmoscopy; 
* Stereo and mono fundus color slides. 
APPENDIX 
The members of the four project groups and 
collaborating research groups are given in this 
Appendix. 
Neurogeriatric diseases 
A. Hofman, MD, Ph.D, principal investigator, 
Department of Epidemiology and Biostatistics, 
Erasmus University, Rotterdam; M.M.B. Breteler, MD, 
Department of Epidemiology and Biostatistics, 
Erasmus University, Rotterdam; J.J. Claus, MD, 
Department of Epidemiology and Biostatistics, 
Erasmus University, Rotterdam; T.J.M. van der 
Cammen, MD, Department of Internal Medicine 
I/Geriatrics, Erasmus University, Rotterdam; F. van 
Harskarnp, MD, Department of Neurology, Dijkzigt, 
Erasmus University, Rotterdam; C.M. van Duyn, MSc, 
Department of Epidemiology and Biostatistics, 
Erasmus University, Rotterdam; W.J. Schudel, MD, 
Ph.D, Department of Psychiatry, Dijkzigt, Erasmus 
University, Rotterdam. 
Collaborating roups include IVEG/TNO (Prof. 
D.L. Knook), Department of Biochemistry, University 
of Antwerp (Dr C. Van Broeckhoven), Department of 
Biochemistry, University of London (Dr J. Hardy), 
Psychiatric Centre, VU Amsterdam (Prof. W. van 
Tilburg), Department of Neurology, Academic 
Hospital, Utrecht (Prof. J. van Gijn), EURODEM 
Concerted Action on the Epidemiology of Dementia, 
Rotterdam, EURAGE, Concerted Action on Ageing 
and Diseases (Prof. D.L. Knook, Rijswijk, The 
Netherlands). 
Cardiovascular diseases 
D.E. Grobbee, MD, PhD, principal investigator, 
Department of Epidemioiogy, Erasmus University, 
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Rotterdam; M.L. Bots, MD, Department of 
Epidemiology and Biostatistics, Erasmus University, 
Rotterdam; P.J. Breslau, MD, PhD, Department of 
Vascular Surgery, Rode Kruis Hospital, Den Haag; E. 
Bri~t, MD, PhD, Department of Hemostasis and 
Thrombosis Research, Academic Hospital, Leiden; F. 
Haverkate, PhD, project leader European Concerted 
Action on Thrombosis and Disabilities, Gaubius 
Institute-TNO, Leiden; P. Koudstaal, MD, PhD, 
Department of Neurology, Erasmus University, 
Rotterdam; J.P. Mackenbach, MD, PhD, Department of 
Public Health, Erasmus University, Rotterdam; H. 
Pleumeekers, MD, Departments of Family Practice and 
Epidemiology, Erasmus University, Rotterdam; H. 
Raat, MD, Municipal Health Service, Rotterdam; F.R. 
Rosendaal, MD, PhD, Department of Hemostasis and 
Thrombosis Research and Dept. of Clinical 
Epidemiology, Academic Hospital, Leiden; R.P Stolk, 
MD, Department of Epidemiology and Biostatistics, 
Erasmus University, Rotterdam; J.C. van Swieten, MD, 
Department of Neurology, Academic Hospital, Utrecht; 
H.H.D.M. van Vliet, PhD, Department ofHematology, 
Academic Hospital, Rotterdam; J.C.M. Witteman, 
MSc, Department of Epidemiology and Biostatistics, 
Erasmus University, Rotterdam. 
Collaborating scientists include J.H. van Bemmel, 
PhD, Department of Medical Informatics, Erasmus 
University, Rotterdam; E. van der Does, MD, PhD, 
Department of General Practice, Erasmus University, 
Rotterdam; A.F. Casparie, School of Health Policy and 
Management, Erasmus University, Rotterdam; J. van 
Gijn, MD, PhD, Department of Neurology, Academic 
Hospital, Utrecht; G. Heiss, MD, Atherosclerosis Risk 
in the Community Study, University of North Carolina 
at Chapel Hill, USA; J.J.C. Jonker, MD, STAR 
Laboratory, Rotterdam; F.J. Kok, PhD, CIVO/TNO, 
Zeist; E.A. Loeliger, MD, PhD, Department of 
Hemostasis and Thrombosis research, Academic 
Hospital, Leiden; T.W. Meade, MD, MRC 
Epidemiology and Medical Care Unit, Northwick Park 
Hospital, Middlesex (UK); C. van der Meer, 
Department of Biochemistry, University of Limburg, 
Maastricht; R. Reneman, MD, PhD Department of 
Physiology, University of Limburg, Maastricht; 
J.T.R.C. Roelandt, MD, PhD, Department of 
Cardiology, Thorax center, Erasmus University, 
Rotterdam; J.C. van Swieten, MD, Department of 
Neurology, Academic Hospital, Utrecht; H. van Urk, 
MD, PhD, Department of Surgery, Erasmus University, 
Rotterdam; H.A. Valkenburg, MD, PhD, EMGO 
Institute, Free University, Amsterdam; R.F.A. Weber, 
MD, PhD, Department of Internal Medicine III, EUR; 
J. Wikstrand, MD, PhD, Wallenberg Laboratory for 
Cardiovascular Research, Gothenburg, Sweden. 
Locomotor diseases 
F.A. van den Ouweland, MD, PhD, principal 
investigator, Department of Epidemiology and 
Biostatistics, Erasmus University, Rotterdam; J.C. 
Birkenh~iger, MD, PhD, Department of Medicine III, 
Academic Hospital, Rotterdam; H.E. Schfitte, MD, 
PhD, Department of Radiology, Academic Hospital, 
Rotterdam; E. Odding, MD, Department of 
Epidemiology and Biostatistics, Erasmus University, 
Rotterdam; J.S.A.G. Schouten, MD, Department of 
Epidemiology and Biostatistics, Erasmus University, 
Rotterdam; H.A. Valkenburg, MD, PhD, EMGO 
Institute, Free University Amsterdam; P. Lips, MD, 
PhD, Division of Endocrinology, Department of 
Medicine, Free University Amsterdam; A. Hofman, 
MD, PhD, Department of Epidemiology and 
Biostatistics, Erasmus University, Rotterdam. 
This study participates in the European Vertebral 
Osteoporosis Study (A. Silman, ARC Epidemiology 
Research Clinic, Manchester, UK). 
Ophthalmologic diseases 
P.T.V.M. de Jong, MD, PhD, FCOphth principal 
investigator, Institute of Ophthalmology, Erasmus 
University, Rotterdam, and Dept. of Epidemiology and 
Biostatistics, Erasmus University, Rotterdam; I.
Dielemans, MD, Institute of Ophthalmology, Erasmus 
University, Rotterdam; J.R. Vingerling, MD, Institute 
of Ophthalmology, Erasmus University, Rotterdam. 
The study protocol was drafted in close 
collaboration with the Inner City Eye Study in London 
(Dept. of Preventive Ophthalmology, Cayton Street, 
Prof G.J. Johnson with the National Eye Institute (NIH 
Bethesda, USA), the Wilmer Eye Institute, Baltimore 
(USA) and the University of Erlangen (BRD) in order 
to ensure comparability with previous and current 
epidemiological studies. 
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